Hepion pharmaceuticals announces postponement of 2021 annual meeting of stockholders

Edison, n.j., july 23, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("nash"), today announced the postponement of its adjourned 2021 annual meeting of stockholders (the "annual meeting") that was to be held on july 23, 2021, at 9:00 a.m. eastern time due to a lack of a quorum. the meeting will be rescheduled for a date yet to be determined by the board of directors. the board of directors will establish a new record date for the annual meeting and, based on this record date, the company will deliver a notice of the new annual meeting date to stockholders entitled to receive notice of the annual meeting.
HEPA Ratings Summary
HEPA Quant Ranking